Clinical trials: Hepatitis; Epidemic
HIV Infections, Liver Toxicity
Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
The purpose of this study is to demonstrate the difference in frequency and level of liver function disturbance between patients on efavirenz based ART, and patients on nevirapine based ART in HBV and HCV co-infected patients…
- Conditions
- HIV Infections, Liver Toxicity, Hepatitis Co-infection
- Trial name
- NCT01273142
- Volunteers
- 100 people
- Sponsor
- Henan Provincial People's Hospital
Transplant-Related Disorder, Hepatitis B Virus Infection
Optimal Timing of Hepatitis B Vaccination After Transplants
The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different…
- Conditions
- Transplant-Related Disorder, Hepatitis B Virus Infection, Vaccine Reaction
- Trial name
- NCT06888479
- Testing
- hepatitis B vaccine
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hepatitis C, Chronic
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
The aim of the study is to confirm efficacy of treatment for 16 and 24 weeks in chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.
- Trial name
- NCT01732796
- Testing
- Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127
- Where
- 101 sites in United States, Austria and 12 more
- Volunteers
- 470 people
- Sponsor
- Boehringer Ingelheim
Cirrhosis, Alcohol Related Liver Disease
Clinical Characteristics of Recompensation
Recompensation in decompensated liver cirrhosis is an emerging clinical endpoint; however, standardized criteria and long-term prognostic data are currently lacking.
- Conditions
- Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus), Recompensation
- Trial name
- NCT07651683
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B
Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns
The primary purpose of this study is to determine whether HepavaxGene TF is non-inferior to the comparator vaccine both at impeding hepatitis B transmission from mothers positive for chronic hepatitis B (Stratum 1) to their…
- Trial name
- NCT01349283
- Testing
- HepavaxGene (thiomersal free), Engerix B
- Where
- China
- Volunteers
- 1,738 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Hepatitis C Virus Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir…
- Trial name
- NCT02185794
- Testing
- Voxilaprevir, SOF/VEL
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus Infection
Absolute Bioavailability of BMS-791325
The purpose of this study is to determine the absolute bioavailability of 150 mg oral dose of BMS-791325 relative to 100 µg IV infusion of [13C]-BMS-791325.
- Trial name
- NCT02112110
- Testing
- BMS-791325, [13C]-BMS-791325
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis A, Hepatitis B
Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine
The purpose of this study is to compare the immunogenicity and safety of three different immunization schedules of inactivated hepatitis A vaccine (HAV) and/ or combined hepatitis A and B vaccine (HABV) in healthy Chinese infants.
- Trial name
- NCT02445703
- Testing
- Inactivated Hepatitis A vaccine (HAV), Combined hepatitis A and hepatitis B vaccine (HABV)
- Where
- China
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hepatitis C
Class II Invariant Chain HCV Vaccine Study
The study is aimed at assessing the safety and immunogenicity of HCV prime-boost vaccinations ChAd3-hliNSmut and MVA-hliNSmut, administered intramuscularly in healthy volunteers and DAA treated patients.
- Trial name
- NCT03688061
- Testing
- ChAd3-hliNSmut, MVA-hliNSmut
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Liver Fibrosis
Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.
This study was a randomized, double-blind, placebo-controlled, entecavir basic treatment, multicentre clinical study. The main objective of this study was to confirm the efficacy and safety of hydronidone in the treatment of…
- Trial name
- NCT05115942
- Testing
- Hydronidone capsules
- Where
- 44 sites in China
- Volunteers
- 248 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
HIV/AIDS, Hepatitis C
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
This study will test two active evidence-based "practice coaching" (PC) interventions to improve opioid treatment programs' (OTPs') provision and sustained implementation of on-site 1) HIV testing and linkage to care and 2)…
- Conditions
- HIV/AIDS, Hepatitis C, Substance Use Disorders, Opioid-use Disorder
- Trial name
- NCT03135886
- Testing
- Information Control, HIV and HCV Testing Practice Coaching Intervention, HIV Testing Practice Coaching Intervention
- Where
- United States
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Columbia University
Hepatitis B
A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years
This study is conducted to assess safety and immunogenicity of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system in healthy, HBs naïve, adults aged 18-45 years and to differentiate GSK's AS37 adjuvant system from…
- Trial name
- NCT05561673
- Testing
- GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system, GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system
- Where
- 5 sites in Belgium, Germany and 1 more
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HBeAg-negative Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940341
- Testing
- TAF, TDF
- Where
- 105 sites in United States, Australia and 15 more
- Volunteers
- 426 people
- Sponsor
- Gilead Sciences
Hepatitis C
Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C
This observational prospective registry is designed to evaluate the safety, adherence, and efficacy of prescribed, patient-administered therapy with Infergen® (Interferon alfacon 1) and other prescribed therapies in patients…
- Trial name
- REACHSVR (NCT00951223)
- Testing
- Infergen® (Interferon alfacon-1)
- Sponsor
- Kadmon Corporation, LLC
Hepatitis
The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial
The purpose of this study is to use entecavir combined with other drug such as resveratrol and thymosin to treat patients with hepatitis B, which may provide a novel therapy target hepatitis B.
- Trial name
- NCT03509688
- Testing
- entecavir+resveratrol, Entecavir, entecavir+thymosin α1
- Volunteers
- 312 people
- Sponsor
- The First Hospital of Jilin University
Chronic Hepatitis C
Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)
Study is a non-interventional, prospective, multicenter post marketing surveillance study to determine the safety of daclatasvir based therapy
- Trial name
- NCT03500562
- Where
- 2 sites in China
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
PT-NANBH
Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1
The goal of this pilot study is to examine both efficacy and tolerability in patients with HCV genotype 1 and mild decompensation with Child-Pugh-Turcott score of 6 or lower.
- Trial name
- NCT02485080
- Testing
- Simeprevir, Sofosbuvir
- Where
- 2 sites in United States
- Sponsor
- Stanford University
Chronic Hepatitis C
Treatment Insulin Resistence in HCV G-1 Patient
To evaluate the effect of treatment of insulin resistance in the response of chronic hepatitis C treatment, mesure as HCV-RNA negative at week 72.
- Trial name
- TRIC-1 (NCT00546442)
- Testing
- Metformine
- Where
- 19 sites in Spain
- Volunteers
- 126 people
- Sponsor
- Valme University Hospital
Chronic Hepatitis
Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT
Entecavir (ETV) has shown superior ability to suppress hepatitis B virus (HBV) replication, histology improvement as well as low rate of emergence of resistant mutants.
- Trial name
- NCT01833611
- Testing
- Entecavir
- Where
- 4 sites in Taiwan
- Volunteers
- 130 people
- Sponsor
- National Cheng-Kung University Hospital
Hepatitis C
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
The aim of the study is to determine if treatment for recently acquired hepatitis C infection (with or without HIV coinfection) can be shortened when treating with the interferon-free therapy sofosbuvir/velpatasvir (SOF/VEL).
- Trial name
- REACT (NCT02625909)
- Testing
- SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 222 people
- Sponsor
- Kirby Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.